Case of semen-mediated antibiotic anaphylaxis prompts calls to update drug labeling for post-coital exposure risks

The index case involved a patient with no prior drug allergy who experienced systemic symptoms minutes after intercourse with a partner prescribed an antibiotic excreted in semen. Clinicians traced the reaction to trace drug concentrations transferred during ejaculation, confirmed via timing and symptom pattern. This mechanism, though rare, aligns with known pharmacokinetics of certain antibiotics that achieve detectable seminal fluid levels.

Existing pharmacovigilance systems focus on direct ingestion or topical contact, overlooking mucosal absorption during sexual activity. Related reports in dermatology and allergy literature document similar transfers with other medications, yet labeling rarely addresses partner exposure. Regulatory bodies like the EMA and FDA have updated leaflets for select drugs after isolated cases, but systemic review of semen-mediated risks remains absent.

Public health impact centers on patients prescribed common urinary tract infection antibiotics who are sexually active. Adding explicit warnings could prompt partners to use barrier methods or delay intercourse, reducing emergency visits. However, without incidence data, the change risks over-warning and reduced adherence.

Next steps include targeted pharmacoepidemiology studies using electronic health records to quantify frequency and a formal petition to medicines regulators for label revision within two years.